0001562180-20-001937.txt : 20200302
0001562180-20-001937.hdr.sgml : 20200302
20200302192924
ACCESSION NUMBER: 0001562180-20-001937
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200228
FILED AS OF DATE: 20200302
DATE AS OF CHANGE: 20200302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dahan Michel
CENTRAL INDEX KEY: 0001669737
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 20679307
MAIL ADDRESS:
STREET 1: C/O AKEBIA THERAPEUTICS, INC.
STREET 2: 245 FIRST STREET, SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-02-28
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001669737
Dahan Michel
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
SVP, Chief Operating Officer
Common Stock
2020-02-28
4
A
false
65000.00
0.00
A
211932.00
D
Common Stock
2020-02-28
4
S
false
6972.00
8.70
D
204960.00
D
Stock Option (Right to buy)
8.87
2020-02-28
4
A
false
120000.00
0.00
A
2030-02-28
Common Stock
120000.00
120000.00
D
The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.
This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.
The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.
/s/ Nicole R. Hadas, attorney-in-fact for Michel Dahan
2020-03-02